{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:59:44Z","timestamp":1774583984680,"version":"3.50.1"},"reference-count":31,"publisher":"Walter de Gruyter GmbH","issue":"9","license":[{"start":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2018-1369_s_999_w2aab3b7c84b1b6b1aab1c17b1Aa\">\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder with a high risk of progression to symptomatic multiple myeloma (MM). The serum free light chain (sFLC) ratio is a powerful prognostic factor for SMM: an sFLC ratio \u22658 has been reported to be associated with a high risk of progression to MM, and an sFLC ratio \u2265100 has been described as a criterion for ultra-high-risk SMM, and has been integrated into the definition criteria for MM since 2014. However, all recommendations were based on sFLC measured using the first commercialized assay, Freelite\u2122, while other assays are now available. We aimed to evaluate the safety and accuracy of N-Latex sFLC to identify high-risk and ultra-high-risk SMM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2018-1369_s_998_w2aab3b7c84b1b6b1aab1c17b2Aa\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The sFLC ratio was measured at diagnosis with both Freelite and N-Latex assays in a cohort of 176 SMM patients on a BN Prospec nephelometer. Demographic, clinical, therapeutic and laboratory data were collected at the time of diagnosis and at follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2018-1369_s_997_w2aab3b7c84b1b6b1aab1c17b3Aa\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixty-two patients (35.2%) progressed to MM within 2 years. Compared to Freelite\u2122 sFLC, N Latex sFLC ratios \u22658 and \u2265100 provided similar performances for the identification of high-risk and ultra-high risk SMM patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2018-1369_s_996_w2aab3b7c84b1b6b1aab1c17b4Aa\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results evidenced that the N-Latex assay could be used for SMM monitoring, like Freelite. However, an N-Latex sFLC ratio \u226570 appears to provide similar performances to a Freelite sFLC ratio \u2265100, with a slightly better positive predictive value. Both assays provided accurate identification of high-risk and ultra-high risk SMM patients. These results should be confirmed in an independent study.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2018-1369","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T09:49:38Z","timestamp":1555062578000},"page":"1397-1405","source":"Crossref","is-referenced-by-count":12,"title":["Prognostic value of involved\/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients"],"prefix":"10.1515","volume":"57","author":[{"given":"Basile","family":"Henriot","sequence":"first","affiliation":[{"name":"Service de M\u00e9decine Interne , H\u00f4pital Sud CHU Rennes , Rennes , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Rouger","sequence":"additional","affiliation":[{"name":"Laboratoire de Biochimie-Toxicologie , H\u00f4pital Pontchaillou CHU Rennes , Rennes , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chlo\u00e9","family":"Rousseau","sequence":"additional","affiliation":[{"name":"Pharmacologie Biostatistique , H\u00f4pital Pontchaillou CHU Rennes , Rennes , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Escoffre","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie Clinique , H\u00f4pital Pontchaillou CHU Rennes , Rennes , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"S\u00e9billot","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie Clinique , H\u00f4pital Pontchaillou CHU Rennes , Rennes , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Bendavid","sequence":"additional","affiliation":[{"name":"Laboratoire de Biochimie-Toxicologie , H\u00f4pital Pontchaillou CHU Rennes , Rennes , France"},{"name":"Univ Rennes, INSERM, INRA, Institut NuMeCan, CHU Rennes , Rennes , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Minvielle","sequence":"additional","affiliation":[{"name":"CRCINA, INSERM, CNRS , Universit\u00e9 de Nantes, Universit\u00e9 d\u2019Angers , Nantes , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Avet-Loiseau","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de G\u00e9nomique du My\u00e9lome , Rangueil CHU Toulouse , Toulouse , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Decaux","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne , H\u00f4pital Sud CHU Rennes , Rennes , France"},{"name":"Service d\u2019H\u00e9matologie Clinique , H\u00f4pital Pontchaillou CHU Rennes , Rennes , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Moreau","sequence":"additional","affiliation":[{"name":"Laboratoire de Biochimie-Toxicologie , H\u00f4pital Pontchaillou CHU Rennes , Rennes , France"},{"name":"Univ Rennes, INSERM, INRA, Institut NuMeCan, CHU Rennes , Rennes , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2019,4,11]]},"reference":[{"key":"2023033110071933949_j_cclm-2018-1369_ref_001_w2aab3b7c84b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma, and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749\u201357.","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_002_w2aab3b7c84b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111:785\u20139.","DOI":"10.1182\/blood-2007-08-108357"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_003_w2aab3b7c84b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215\u201324.","DOI":"10.1038\/leu.2008.307"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_004_w2aab3b7c84b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2013;27:941\u20136.","DOI":"10.1038\/leu.2012.296"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_005_w2aab3b7c84b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J 2018;8:59.","DOI":"10.1038\/s41408-018-0077-4"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_006_w2aab3b7c84b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Corral L, Guti\u00e9rrez NC, Vidriales MB, Mateos MV, Rasillo A, Garc\u00eda-Sanz R, et al. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res Off J Am Assoc Cancer Res 2011;17:1692\u2013700.","DOI":"10.1158\/1078-0432.CCR-10-1066"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_007_w2aab3b7c84b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356:2582\u201390.","DOI":"10.1056\/NEJMoa070389"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_008_w2aab3b7c84b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol 2002;20:1625\u201334.","DOI":"10.1200\/JCO.2002.20.6.1625"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_009_w2aab3b7c84b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Ravi P, Kumar S, Larsen JT, Gonsalves W, Buadi F, Lacy MQ, et al. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J 2016;6:e454.","DOI":"10.1038\/bcj.2016.65"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_010_w2aab3b7c84b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez de Larrea C, Isola I, Pereira A, Cibeira MT, Magnano L, Tovar N, et al. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Leukemia 2018;32:1427\u201334.","DOI":"10.1038\/s41375-018-0013-4"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_011_w2aab3b7c84b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538\u201348.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_012_w2aab3b7c84b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Wu V, Moshier E, Leng S, Barlogie B, Cho HJ, Jagannath S, et al. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv 2018;2:1470\u20139.","DOI":"10.1182\/bloodadvances.2018016998"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_013_w2aab3b7c84b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673\u201380.","DOI":"10.1093\/clinchem\/47.4.673"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_014_w2aab3b7c84b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"te Velthuis H, Knop I, Stam P, van den Broek M, Bos HK, Hol S, et al. N Latex FLC \u2013 new monoclonal high-performance assays for the determination of free light chain kappa and lambda. Clin Chem Lab Med 2011;49:1323\u201332.","DOI":"10.1515\/CCLM.2011.624"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_015_w2aab3b7c84b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Campbell JP, Heaney JL, Shemar M, Baldwin D, Griffin AE, Oldridge E, et al. Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum \u03ba and \u03bb immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool. Clin Chem Lab Med 2017; 55:424\u201334.","DOI":"10.1515\/cclm-2016-0194"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_016_w2aab3b7c84b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Jacobs JF, de Kat Angelino CM, Brouwers HM, Croockewit SA, Joosten I, van der Molen RG. Evaluation of a new free light chain ELISA assay: bringing coherence with electrophoretic methods. Clin Chem Lab Med 2018;56:312\u201322.","DOI":"10.1515\/cclm-2017-0339"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_017_w2aab3b7c84b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Hoedemakers RM, Pruijt JF, Hol S, Teunissen E, Martens H, Stam P, et al. Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis. Clin Chem Lab Med 2012;50:489\u201395.","DOI":"10.1515\/cclm.2011.793"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_018_w2aab3b7c84b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Di Noto G, Cimpoies E, Dossi A, Paolini L, Radeghieri A, Caimi L, et al. Polyclonal versus monoclonal immunoglobulin-free light chains quantification. Ann Clin Biochem 2015;52:327\u201336.","DOI":"10.1177\/0004563214553808"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_019_w2aab3b7c84b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Hutchison CA, Cockwell P, Cook M. Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy. BMC Clin Pathol 2012;12:12.","DOI":"10.1186\/1472-6890-12-12"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_020_w2aab3b7c84b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Carr-Smith HD, Jenner EL, Evans JA, Harding SJ. Analytical issues of serum free light chain assays and the relative performance of polyclonal and monoclonal based reagents. Clin Chem Lab Med 2016;54:997\u20131003.","DOI":"10.1515\/cclm-2015-1068"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_021_w2aab3b7c84b1b6b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Moreau C, Autier B, Cavey T, Rouger E, Norwood J, Bendavid C, et al. Evaluation of the impact of renal failure on correlation and concordance between 2 free light chain assays. Clin Lymphoma Myeloma Leuk 2016;16:693\u2013704.","DOI":"10.1016\/j.clml.2016.08.012"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_022_w2aab3b7c84b1b6b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Sabatino R, Perrone A, Cuomo M, Liotti S, Barchiesi V, Cantile M, et al. Analytical criticalities associated to different immunological methods for serum free light chain detection in plasma cell dyscrasias: a description of particular clinical cases. Int J Mol Sci 2017;18:804.","DOI":"10.3390\/ijms18040804"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_023_w2aab3b7c84b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Messiaen A-S, De Sloovere MM, Claus P-E, Vercammen M, Van Hoovels L, Heylen O, et al. Performance evaluation of serum free light chain analysis: nephelometry vs. turbidimetry, monoclonal vs. polyclonal reagents. Am J Clin Pathol 2017;147:611\u201322.","DOI":"10.1093\/ajcp\/aqx037"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_024_w2aab3b7c84b1b6b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med 2011;365:474\u20135.","DOI":"10.1056\/NEJMc1106428"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_025_w2aab3b7c84b1b6b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Atrash S, Robinson M, Slaughter D, Aneralla A, Brown T, Robinson J, et al. Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma. Blood Cancer J 2018;8:107.","DOI":"10.1038\/s41408-018-0144-x"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_026_w2aab3b7c84b1b6b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"Aljama MA, Sidiqi MH, Lakshman A, Dispenzieri A, Jevremovic D, Gertz MA, et al. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Adv 2018;2:3149\u201354.","DOI":"10.1182\/bloodadvances.2018024794"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_027_w2aab3b7c84b1b6b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"Kastritis E, Terpos E, Moulopoulos L, Spyropoulou-Vlachou M, Kanellias N, Eleftherakis-Papaiakovou E, et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia 2013;27:947\u201353.","DOI":"10.1038\/leu.2012.309"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_028_w2aab3b7c84b1b6b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"S\u00f8rrig R, Klausen TW, Salomo M, Vangsted AJ, \u00d8stergaard B, Gregersen H, et al. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study. Eur J Haematol 2016;97:303\u20139.","DOI":"10.1111\/ejh.12728"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_029_w2aab3b7c84b1b6b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Gonz\u00e1lez-Calle V. Smoldering Multiple Myeloma: Who and When to Treat. Clin Lymphoma Myeloma Leuk 2017; 17:716\u201322.","DOI":"10.1016\/j.clml.2017.06.022"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_030_w2aab3b7c84b1b6b1ab2b2c30Aa","doi-asserted-by":"crossref","unstructured":"Kumar SK. Timing of treatment of smoldering myeloma: delay until progression. Blood Adv 2018;2:3050\u20133.","DOI":"10.1182\/bloodadvances.2018021238"},{"key":"2023033110071933949_j_cclm-2018-1369_ref_031_w2aab3b7c84b1b6b1ab2b2c31Aa","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Gonz\u00e1lez-Calle V. Timing of treatment of smoldering myeloma: early treatment. Blood Adv 2018;2:3045\u20139.","DOI":"10.1182\/bloodadvances.2018021220"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2019.57.issue-9\/cclm-2018-1369\/cclm-2018-1369.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2018-1369\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2018-1369\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T11:08:04Z","timestamp":1680260884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2018-1369\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,11]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,4,5]]},"published-print":{"date-parts":[[2019,8,27]]}},"alternative-id":["10.1515\/cclm-2018-1369"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2018-1369","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,11]]}}}